FTC approves Mylan's hostile Perrigo bid; Eylea leap pulls Regeneron sales up 57%;

@FiercePharma: GSK's vaccine unit sees revenue, profit jump in Q3. More from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient. Story | Follow @CarlyHFierce

> The FTC has approved Mylan's ($MYL) hostile bid for Perrigo ($PRGO) under the condition that Mylan sell 7 drugs to Alvogen. Report

> Another surge in Eylea sales drove Regeneron ($REGN) to a 57% increase in Q3 revenue, and net income more than doubled. Report

> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release

Medical Device News

@FierceMedDev: Roche launches rapid HIV, hep C tests in Europe. Article | Follow @FierceMedDev

@VarunSaxena2: Medtronic releases health economics study of its drug-coated balloon at Las Vegas conference. Story | Follow @VarunSaxena2

@EmilyWFierce: Does AstraZeneca own the color purple? On a pill, yes, the company contends. FiercePharmaMarketing story | Follow @EmilyWFierce

> Theranos CEO heeds call for transparency for proprietary technology. Article

> Medtronic axes 150 jobs in new Irish tax domicile. News

Biotech News

@FierceBiotech: Biogen spells out its moonshot R&D strategy amid deep cost cuts. More | Follow @FierceBiotech

@JohnCFierce: Oxford team spotlights promise of AstraZeneca drug in targeting cancers. FierceBiotechResearch article | Follow @JohnCFierce

> Flagship launches another microbiome biotech with $35M and a focus on cancer. Report

> Allergan bets $50M on a dry eye drug as it touts its commitment to R&D. Story

> Vertex looks to gene therapy, RNA deals to quash takeover talk. Article

Pharma Marketing News

> GlaxoSmithKline's HIV bright spot could get brighter with new Tivicay combo meds. Item

> Viewers skeptical of DTC ads, but they drive people to docs anyway. More

> Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push. Story

> Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd. Report

> Does AstraZeneca own the color purple? On a pill, yes, the company contends. Article

Biotech Research News

> Neat 'trick' guards peptides against early degradation. Story

> JAK inhibitors target senescent cells in aging study. Item

> Small molecule used to blunt glioblastoma growth in mice--UCSD. More

> Researchers devise heat-triggered liposome 'grenades' to destroy cancer cells. Story

> UPenn researchers show importance of calcium signaling for Ebola virus. Article

Vaccines News

> Takeda, Hilleman eye low-cost vaccine space. News

> Sanofi expects first dengue vaccine license in Q4. Item

> Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa. Report

> GSK's vaccine unit sees revenue, profit jump in Q3. Story

> European Commission launches €23M HIV vaccine research initiative. Article

And Finally... These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.